Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

03 Apr 2012
Director/PDMR Share Dealings

April 3, 2012 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”) announces that it was notified on April 2, 2012 that on March 30, 2012 the Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) in the Company set out below had been awarded under the Shire Executive Annual Incentive Plan (“EAIP”) to Persons Discharging Managerial Responsibility (“PDMRs”). The Shares and ADSs were acquired on March 30, 2012, at prices of £21.11 per Share and $97.3685 per ADS, respectively.

 Type of SecurityNo of Shares/ADSs purchased
Angus Russell (Chief Executive Officer)ADSs2,907
Graham Hetherington (Chief Financial Officer)Shares4,552
Michael ColaADSs1,205
Barbara DeptulaADSs846
Sylvie GregoireADSs1,410
Tatjana MayShares2,660
Kevin RakinADSs442

The awards will not normally be released to participants for three years.  One ADS is equal to three Shares.

In addition, the Company was notified on April 2, 2012 of the release, on the same day, of the following Shares and ADSs awarded in 2009 under the EAIP.

 Type of SecurityNo of Shares/ADSs releasedNo of Shares/ADSs sold to satisfy tax liabilities
Angus Russell (Chief Executive Officer)Shares37,81412,264
Graham Hetherington (Chief Financial Officer)Shares9,0074,659
Michael ColaADSs6,3742,447
Barbara DeptulaADSs4,9022,029
Sylvie GregoireADSs5,6312,236
Tatjana MayShares14,0107,246

On April 2, 2012 sufficient Shares and ADSs were sold to satisfy tax liabilities as set out above.  The Shares were sold at a price of £20.14 per Share and the ADSs were sold at an average price of $97.8240 per ADS.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary


For further information please contact:

Investor Relations  
Eric 781 482 0999
Sarah 1256 894157


Notes to editors


Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website:

03 Apr 2012 Director/PDMR Share Dealings (91KB PDF)

« Back to Shire news

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device